A detailed history of Barclays PLC transactions in Astrazeneca PLC stock. As of the latest transaction made, Barclays PLC holds 462,250 shares of AZN stock, worth $31.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
462,250
Previous 462,250 -0.0%
Holding current value
$31.2 Million
Previous $36 Million -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$76.67 - $87.62 $2.35 Million - $2.69 Million
-30,667 Reduced 6.22%
462,250 $36 Million
Q2 2024

Aug 14, 2024

SELL
$66.81 - $80.83 $26.7 Million - $32.3 Million
-399,632 Reduced 44.77%
492,917 $38.4 Million
Q1 2024

May 15, 2024

BUY
$61.03 - $69.57 $14.2 Million - $16.2 Million
232,498 Added 35.22%
892,549 $60.5 Million
Q4 2023

Feb 15, 2024

SELL
$61.89 - $69.28 $36 Million - $40.3 Million
-582,380 Reduced 46.87%
660,051 $44.5 Million
Q3 2023

Nov 07, 2023

BUY
$64.85 - $71.7 $61.3 Million - $67.7 Million
944,765 Added 317.39%
1,242,431 $84.1 Million
Q2 2023

Aug 03, 2023

SELL
$69.91 - $75.81 $640,515 - $694,571
-9,162 Reduced 2.99%
297,666 $21.3 Million
Q1 2023

May 04, 2023

SELL
$63.15 - $71.6 $2.69 Million - $3.05 Million
-42,633 Reduced 12.2%
306,828 $21.3 Million
Q4 2022

Feb 13, 2023

BUY
$54.21 - $70.44 $12.2 Million - $15.9 Million
225,731 Added 182.44%
349,461 $23.7 Million
Q3 2022

Nov 03, 2022

SELL
$53.02 - $135.75 $5.24 Million - $13.4 Million
-98,798 Reduced 44.4%
123,730 $6.79 Million
Q2 2022

Aug 12, 2022

BUY
$59.26 - $71.14 $12.2 Million - $14.6 Million
205,620 Added 1216.11%
222,528 $14.7 Million
Q1 2022

May 16, 2022

SELL
$55.72 - $67.12 $22.4 Million - $27 Million
-402,616 Reduced 95.97%
16,908 $1.12 Million
Q4 2021

Feb 14, 2022

BUY
$54.02 - $63.83 $21.8 Million - $25.8 Million
404,405 Added 2674.81%
419,524 $24.4 Million
Q3 2021

Nov 09, 2021

SELL
$55.56 - $60.79 $22 Million - $24.1 Million
-396,317 Reduced 96.33%
15,119 $908,000
Q2 2021

Aug 13, 2021

BUY
$48.42 - $60.18 $19.9 Million - $24.7 Million
411,027 Added 100495.6%
411,436 $24.6 Million
Q1 2021

May 13, 2021

SELL
$47.16 - $54.44 $12.5 Million - $14.4 Million
-264,715 Reduced 99.85%
409 $20,000
Q4 2020

Feb 11, 2021

BUY
$48.52 - $58.02 $12.8 Million - $15.3 Million
264,077 Added 25222.25%
265,124 $13.3 Million
Q3 2020

Nov 12, 2020

SELL
$53.07 - $61.1 $2.1 Million - $2.42 Million
-39,609 Reduced 97.42%
1,047 $58,000
Q2 2020

Aug 12, 2020

SELL
$43.1 - $55.31 $2.6 Million - $3.34 Million
-60,357 Reduced 59.75%
40,656 $2.15 Million
Q1 2020

May 13, 2020

SELL
$37.79 - $51.33 $4.87 Million - $6.62 Million
-128,903 Reduced 56.07%
101,013 $4.51 Million
Q4 2019

Feb 10, 2020

BUY
$42.46 - $50.46 $6.29 Million - $7.47 Million
148,058 Added 180.87%
229,916 $11.5 Million
Q3 2019

Nov 14, 2019

SELL
$40.12 - $45.47 $35.6 Million - $40.3 Million
-887,375 Reduced 91.55%
81,858 $3.65 Million
Q2 2019

Aug 14, 2019

BUY
$37.28 - $41.68 $32.1 Million - $35.9 Million
861,601 Added 800.51%
969,233 $40 Million
Q1 2019

May 15, 2019

SELL
$35.49 - $43.02 $123,611 - $149,838
-3,483 Reduced 3.13%
107,632 $4.35 Million
Q4 2018

Feb 14, 2019

BUY
$36.86 - $41.49 $47,475 - $53,439
1,288 Added 1.17%
111,115 $4.22 Million
Q3 2018

Nov 14, 2018

BUY
$34.76 - $39.72 $136,120 - $155,543
3,916 Added 3.7%
109,827 $4.35 Million
Q2 2018

Aug 14, 2018

SELL
$34.55 - $37.05 $1.39 Million - $1.49 Million
-40,308 Reduced 27.57%
105,911 $3.72 Million
Q1 2018

May 15, 2018

SELL
$32.97 - $36.63 $1.51 Million - $1.68 Million
-45,736 Reduced 23.83%
146,219 $5.11 Million
Q4 2017

Feb 14, 2018

BUY
$32.09 - $34.78 $339,736 - $368,215
10,587 Added 5.84%
191,955 $6.66 Million
Q3 2017

Nov 14, 2017

BUY
$28.96 - $34.0 $5.25 Million - $6.17 Million
181,368
181,368 $6.14 Million

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $209B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.